

# New Launched M-TEER Device for Degenerative Mitral Regurgitation: PASCAL Experiences in JAPAN

SHINICHI SHIRAI, MD Kokura Memorial Hospital, Japan



### **Disclosure**

I have the following potentiel conflicts of interest to declare:

Proctor: Abbott, Edwards Lifesciences, Medtronic Speaker honorarium: Edwards Lifesciences, Medtronic,





### 79 y.o Woman Severe MR d/t P2 prolapse

PSL user (Erythema nodosum), Hx of LK, Primary sclerotic cholangitis, No cognitive dysfunction











### The PASCAL Precision transcatheter valve system



## **2 types of PASCAL implant**

#### PASCAL and PASCAL Ace

### **The PASCAL & PASCAL Ace implants**

For degenerative mitral regurgitation



#### PASCAL implant



# **Trans-septal puncture**



### **Guide sheath insertion**

#### Extremely easy to penetrate the septum and femoral access site.





**TCTAP2024** 

# Implant system insertion



### **Steering down**

Unlike MitraClip, No posterior movement of guide sheath is needed.



### **Trajectory and PASCAL insertion to LV**



# Paddle opening, grasping and Clasp down



<sup>2</sup> TCTAP 2024



### **Closing the paddle**

But, the posterior leaflet is not enough grasping





### Independent re-grasping of posterior leaflet



**Č** ČVRF



## **Final result**





# Conclusion

- 1) We experienced the first PASCAL Ace implantation for P2 lateral prolapse in Japan.
- 2) Guide sheath was excellent to penetrate the access site and septum because of the seamless structure of the outer and inner sheath.
- 3) Pascal system had an ergonomic handle to manipulate in procedure.
- 4) Although there are some differences, structure is like that of the preceding product, It is also expected that the learning curve would be faster due to familiarity with treatment techniques.
- 5) Compared with preceding product, in PASCAL, MV area loss would be less because of the spacer, and the device number would be saved due to the width of the paddle.



